Renal Macrophage States During Repair: Mechanisms, Clinical Relevance, and Therapeutic Implications

Abstract

Renal macrophages play a pivotal role in tissue homeostasis, injury response, and repair within the kidney. Their diverse activation states, ranging from pro-inflammatory to reparative phenotypes, orchestrate complex processes in acute and chronic kidney injury. Recent advances in single-cell technologies and lineage tracing have illuminated the dynamic transitions and functional heterogeneity of renal macrophages during repair. This review synthesizes current evidence on the mechanisms underlying macrophage plasticity in renal repair, discusses clinical implications, explores risk factors influencing macrophage responses, and highlights emerging therapeutic strategies targeting macrophage states for improved renal outcomes.

Introduction

Renal injury, whether acute or chronic, triggers a robust immune response involving resident and recruited macrophages. These cells exhibit remarkable plasticity, adapting their phenotype and function according to microenvironmental cues. The dichotomous classification of macrophages into M1 (pro-inflammatory) and M2 (anti-inflammatory/reparative) states has evolved, with current research revealing a spectrum of intermediate and context-specific activation states. Understanding these dynamic transitions is crucial for deciphering the mechanisms of renal repair and developing targeted interventions to promote tissue recovery while minimizing fibrosis and progression to chronic kidney disease (CKD).

Epidemiology / Disease Burden

Acute kidney injury (AKI) and CKD are prevalent conditions with significant morbidity and mortality worldwide. Epidemiological studies estimate that AKI affects up to 20% of hospitalized patients, with a substantial proportion progressing to CKD or end-stage renal disease. The burden of kidney disease is exacerbated by the limited regenerative capacity of the adult mammalian kidney and the propensity for maladaptive repair, leading to fibrosis. Macrophage-driven inflammation and repair responses are central to the pathogenesis and outcomes of renal injury, emphasizing the importance of understanding and modulating macrophage states in clinical nephrology.

Pathophysiology

Upon renal injury, damage-associated molecular patterns (DAMPs) from injured tubular epithelial cells activate resident macrophages and facilitate the recruitment of monocyte-derived macrophages. Initially, pro-inflammatory macrophages (classically referred to as M1) dominate, secreting cytokines such as TNF-α, IL-1β, and IL-6, which amplify inflammation and promote further tissue damage. As the injury resolves, a phenotypic shift toward reparative (M2-like) macrophages occurs. These cells secrete anti-inflammatory mediators, including IL-10 and TGF-β, and support tissue remodeling, angiogenesis, and matrix deposition. However, persistent activation or dysregulation of these states can contribute to maladaptive repair and fibrosis. Single-cell RNA sequencing has revealed further heterogeneity, identifying subpopulations with distinct transcriptional profiles and functions, such as pro-angiogenic, profibrotic, and phagocytic macrophages.

Risk Factors

Several factors influence the activation, recruitment, and polarization of renal macrophages during repair. These include the etiology and severity of injury (ischemic, toxic, or immunologic), genetic predispositions, age, underlying comorbidities (diabetes, hypertension), and the local renal microenvironment. Systemic factors such as metabolic dysfunction, dysregulated immune responses, and chronic inflammation modulate macrophage behavior and can predispose to maladaptive repair. Understanding patient-specific risk factors is essential for tailoring interventions aimed at optimizing macrophage-driven repair.

Clinical Features

The clinical manifestations of renal injury and repair are heterogeneous and depend on the balance between injurious and reparative macrophage responses. Acute phases are characterized by oliguria, azotemia, and electrolyte disturbances, often accompanied by systemic inflammatory features. Successful resolution leads to gradual recovery of renal function; however, persistent macrophage activation and ongoing inflammation may result in interstitial fibrosis, tubular atrophy, and progression to CKD. Biomarkers reflective of macrophage activation states, such as urinary and plasma cytokines, are being investigated for their utility in monitoring disease activity and therapeutic response.

Diagnosis

Diagnosis of macrophage-mediated renal injury and repair relies on a combination of clinical assessment, laboratory evaluation, and histopathological analysis. Renal biopsy remains the gold standard for assessing macrophage infiltration, phenotype, and spatial distribution within the kidney. Immunohistochemistry for markers such as CD68 (pan-macrophage), CD80 (M1), and CD206 (M2) provides insights into the predominant macrophage states. Advanced techniques, including multiplex immunofluorescence and single-cell transcriptomics, offer higher-resolution characterization of macrophage heterogeneity and functional states, although these are primarily research tools at present.

Treatment & Management

Current management of renal injury focuses on supportive care, hemodynamic optimization, and mitigation of further insults. Therapeutic strategies targeting macrophage responses are under investigation. Pharmacologic agents such as corticosteroids and immunosuppressants modulate macrophage activation but lack specificity. Efforts are underway to develop treatments that selectively reprogram macrophage states, such as small molecules, biologics targeting cytokine pathways, and nanoparticle-based delivery systems. Cell-based therapies using ex vivo-modified macrophages are also being explored, with the goal of enhancing reparative functions while limiting pro-inflammatory and profibrotic activities.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in understanding renal macrophage biology. Single-cell omics and fate-mapping studies have identified novel subpopulations involved in both injury propagation and repair. Targeting specific signaling pathways, such as CSF1R, CCR2, and TREM2, has shown promise in preclinical models for modulating macrophage recruitment and activation. Therapies aimed at enhancing pro-reparative macrophage functions—such as IL-4/IL-13 agonists, mesenchymal stem cell-derived exosomes, and metabolic reprogramming agents—are being investigated in clinical trials. These approaches hold potential for improving outcomes by promoting regeneration while minimizing fibrosis.

Guideline Recommendations

Current clinical guidelines for AKI and CKD management emphasize early detection, supportive care, and avoidance of nephrotoxic agents. While no specific recommendations exist for therapeutically targeting renal macrophage states, ongoing research is likely to inform future guidelines, particularly as precision medicine approaches and targeted immunomodulation become more feasible. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recognize the importance of inflammation and immune responses in disease progression, underscoring the need for continued research in this area.

Conclusion

Renal macrophages are central orchestrators of injury and repair, exhibiting dynamic and context-dependent activation states. Advances in molecular profiling have expanded our understanding of macrophage heterogeneity and plasticity during renal repair, revealing new therapeutic targets. Optimizing the balance between protective and pathogenic macrophage responses is key to improving outcomes in AKI and CKD. Future research should focus on translating mechanistic insights into clinically effective strategies, with the goal of promoting regenerative repair while preventing fibrosis and chronic disease progression.